Goldman Sachs initiated coverage of NewAmsterdam Pharma (NAMS) with a Neutral rating and $27 price target The firm sees the stock as range-bound with results from the Phase 3 PREVAIL cardiovascular outcomes trial for the company’s lead candidate obicetrapib is not expected until late 2026. However, Goldman is “constructive” on obicetrapib’s LDL-C lowering and other lipid effects.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma Updates Employment Agreement with Executive
- NewAmsterdam Pharma participates in a conference call with Cantor Fitzgerald
- NewAmsterdam Pharma initiated with a Buy at Citi
- Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities
- NewAmsterdam Pharma Schedules R&D Day for June 2025